-
Study budgeting, feasibility, site recruitment
SynCRO has collaboration with qualified investigators in all major therapeutic areas from Romania, Hungary and Moldova.
-
Regulatory affairs, ethic committees
+ Preparation of documents and submission to regulatory authorities and ECs
+ Timely reporting of SUSARs, SAEs. -
Drug import, site initiation
+ Drug import and distribution to centers
+ Site initiation / training of investigators -
Project management, study coordination, monitoring
+ Trial site management / site supplies (laboratory kits, CRFs)
+ Continuous assessment of investigators' compliance with GCP / regulatory requirements -
Clinical Data Management and Biostatistics
Syncro is providing Clinical Data Management and Biostatistics services through it's partner, AdWare Research.
AdWare Research was established in 1997 and it is a dynamically developing pre-clinical and clinical data-management and biostatistics provider company. AdWare provides its service in compliance with the national and international regulations, and possesses the relevant GLP, RA certificates.
+ Data-management and biostatistics
Its main activities are:
+ Quality assurance
+ Independent audit
+ Education and consultancyWith its strategic partners AdWare can undertake whole-scale project management.
The data-management services are provided by its own developed Mythos data-manager software that fulfills the criteria of FDA CFR 21 part 11.
For more information please visit: www.adwareresearch.com
-
21 JAN
2020NEW: QMS development and GCP audits
"Without standards, there can be no improvement" (Taiichi Ohno)
Read more
SynCRO provides consultancy for clinical research sites in the development of QMS and site-specific clinical research SOPs.
In addition, we can perform GCP investigational site audits and vendor qualification audits anywhere in the world. -
04 JUN
2019Patience is bitter, but its fruit is sweet
During the last years there were considerable delays in clinical study approval times in Romania which led to a decreased interest to conduct clinical trials in our country. Towards the end of 2018 the Romanian RA have realized that very prompt and urgent measures must be taken in order to normalize the situation.
Read more